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Xenobiotic-metabolizing enzymes are widely poly-
morphic and confer interindividual variation in the ability to
detoxify carcinogens or to activate pro-carcinogens. A common
polymorphism of cytochrome P450 2D6 (CYP2D6) results in lack of
enzyme activity and has been associated with an altered susceptibility
to several cancers. The aim of this study was to investigate the




 poor metaboliser genotype and the













Genotyping was performed by PCR and restriction












The frequency of individuals with the homozygous poor





























The results suggest that the poor metaboliser
genotype is associated with a protective effect against PTC. This




 on the metabolic
activation of putative environmental chemical thyroid carcinogens
or by linkage to another cancer-causing gene. Further research may
allow the identification of metabolic risk factors and contribute
towards understanding the molecular mechanisms involved in
thyroid carcinogenesis.
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Papillary thyroid cancer (PTC) is the most common form of thyroid




 Exposure to radiation is a
recognized causative factor for PTC but no clear role for chemical









so it is conceivable that these or others may also play a role in the
development of thyroid cancer in humans.
Xenobiotic-metabolizing enzymes constitute one of the first lines
of defence against environmental chemicals, and polymorphisms of
genes encoding several of these enzymes lead to interindividual
differences in enzymatic activity and have been linked to different




 The cytochrome P450 2D6
(CYP2D6) is one of the most thoroughly studied enzymes, as lack









 alleles (poor metaboliser genotype) and this is mostly









 poor metaboliser genotype has





no studies have yet been presented for thyroid cancer.












A retrospective case-control study was performed involving 187
patients with papillary thyroid cancer (39 males 148 female patients,
mean age ± SD, 44·5 ± 15·4 years) and 256 controls (150 male, 106
female patients, mean age ± SD, 36·8 ± 13·7 years) consisting of
healthy volunteers recruited among blood donors and hospital and









 Patients treated at the
University Hospital of Coimbra were consecutively included in the
study at the time of radioiodine therapy, during the period 1998–2003,
and were selected on the basis of histologically confirmed presence
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of one of the two major subtypes of PTC: the classical form and the
follicular variant of PTC. Tumour TNM classification and staging
followed the International Union Against Cancer (UICC) and the




























(nucleotide numbering according to GenBank cDNA sequence
NM_000106, with nucleotide +1 corresponding to the A of the ATG




Briefly, genomic DNA was used in PCR amplification reactions to
generate a 334 bp fragment containing the polymorphic nucleotide.






















, and using 30 cycles


















A polymorphism was detected by loss of the restriction
site, whereas absence of this polymorphism resulted in 230 and 104-
bp-size fragments. Individuals were classified as homozygous exten-
sive metabolisers (two functional alleles), heterozygous extensive











-test of independence, with one degree of freedom,
was used to examine differences of poor metaboliser genotype
frequencies and allele frequencies between patients and controls.
When expected values were less than five, Fisher’s exact test was used
instead. Subgroup analysis was carried out to assess the effect of
tumour histology, multifocality and tumour stage, and Bonferroni’s





-values were calculated and statistical significance




 < 0·05. Odds ratios (OR) and the corresponding 95%
confidence intervals (CI) were also calculated. Hardy–Weinberg






 goodness-of-fit test to








 genotype and allele observed frequencies in patients
and controls are presented in Table 1. Genotypes were in Hardy–
Weinberg equilibrium. The frequency of individuals with the poor
metaboliser genotype was lower in the patient group than in the








 = 0·037, OR = 0·28 (95% CI 0·09–0·93)].
Analysis of allele frequencies revealed a lower frequency of the
















 = 0·002, OR = 0·56 (95% CI 0·39–0·80)]. Table 2 presents the
results of the comparison of subgroups of patients with different
disease severity. Genotype and allele frequencies were not significantly
different between patients with the classical and the follicular variant
of PTC, between patients with unifocal and multifocal tumours, or









metaboliser homozygous genotype in the PTC group, when
compared to the control group. Thus, in our population the poor
metaboliser genotype was associated with a protective effect against
PTC, and individuals with this genotype appear to have an almost
fourfold decrease in risk of PTC. While the functional significance
of this finding is unclear, similar results have been reported for
tumours at other sites, such as lung cancer and leukaemia, for which




Other studies have suggested that the poor metaboliser genotype





possible that the risk genotype varies not only with the type of cancer,
but also with ethnical and geographical contexts that reflect different
genetic backgrounds and environmental exposures.
Although the cytochrome P450 enzymes are generally regarded as
detoxifying enzymes that protect the organism from toxic products,
it should be noted that, in many cases, this metabolism forms toxic
intermediate compounds that are more harmful than the original





 Several environmental carcinogens require





 thus, decreased transformation of pro-carcinogens
by poor metabolisers could result in a protective effect against these
carcinogens.
Table 1. CYP2D6 genotype and allele frequencies in patients with papillary thyroid cancer and in controls
Genotypes [n (%)] Alleles [n (%)]
EM HEM PM non-CYP2D6*4 CYP2D6*4
Controls (n = 256) 159 (62·1) 83 (32·4) 14 (5·5) 401 (78·3) 111 (21·7)
Patients (n = 187) 140 (74·9) 44 (23·5) 3 (1·6) 324 (86·6) 50 (13·4)
OR (95% CI) 0·28 (0·09–0·93) 0·56 (0·39–0·80)
P-value 0·037 0·002
n, number; EM, homozygous extensive metaboliser (two functional alleles); HEM, heterozygous extensive metaboliser (one functional allele); 
PM, poor metaboliser (no functional alleles); OR, odds ratio; CI, confidence interval. P-values were calculated by χ2-analysis.
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Polymorphisms of other xenobiotic-metabolizing enzymes such as
glutathione S-transferase mu-1 and theta-1 have also been associated




 and this greatly
supports the role of xenobiotic-metabolizing enzymes in thyroid
carcinogenesis. A role for chemical carcinogenesis in PTC has not
yet been established in humans, although animal experiments have









 Chromosomal rearrangements are frequent
findings in thyroid cancer cells and are considered to play a role




 It is of interest to note that chromosomal





An alternative explanation for the findings would be the existence




 locus at chromosome
22q13·1 with other neighbouring genes with a yet unidentified role
in thyroid carcinogenesis.




 polymorphism was associated with a less aggressive type
of papillary carcinoma or advanced disease. Genotype and allele
frequencies between the two major histological subtypes of PTC
were not different, despite the different morphology, cytogenetic and
molecular characteristics, and the more aggressive clinical behaviour




 Similarly, no difference was found between
lower and higher tumour stage, or between unifocal and multifocal
PTC.




polymorphisms on the susceptibility to PTC that could be explained




 on the metabolic activation of putative
environmental chemical thyroid carcinogens or by linkage to
another cancer-causing gene. Further research in this field may
allow the identification of metabolic risk factors and contribute
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